The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study
Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…Minimizing levodopa titration period for Parkinson’s disease (PD)
Objective: Develop an optimization algorithm that individualizes the pharmacokinetics-pharmacodynamics (PKPD) infusion models of levodopa, to improve the efficacy of dose titration and reduce the number…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Levodopa, placebo and rotigotine change biomarker levels for oxidative stress
Objective: The objective was to investigate the influence of the D1 receptor agonists levodopa and rotigotine compared with placebo on homocysteine and cysteinyl-glycine in plasma…Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease diagnosis
Objective: To evaluate the diagnostic value of combined acute levodopa challenge and olfactory testing to predict PD diagnosis. Background: Acute levodopa challenge can be used…Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?
Objective: The aim of this study was to explore the angiogenetic hypothesis for Levodopa-induced-dyskinesia (LID) using advanced MRI methods in patients with Parkinson's disease (PD).…Dopaminergic and non-dopaminergic effects on instrumented timed up and go test in patients with Parkinson’s disease
Objective: To evaluate an instrumented version of Timed Up and Go Test (iTUG) in patients with Parkinson's disease (PD), both in L-dopa OFF and ON-state.…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 62
- Next Page »